You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

61 Results
Guidelines and Advice
Status: Archived
ID: DILung
Apr 2012
Guidelines and Advice
Status: Current
ID: GL-C50-02
Jan 2012
Guidelines and Advice
Status: Current
ID: GL-C50-29
Mar 2012
Guidelines and Advice
Status: Current
ID: GL 2-21
Version: 2
Mar 2024
Cancer facts
Jul 2012
Cancer facts
Mar 2012
Guidelines and Advice
Status: Current
Dec 2012
Guidelines and Advice
Status: Education and Information
Dec 2012
Drug
Other Name(s): Revlimid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Drug
Other Name(s): Nubeqa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2024

Pages